Interleukin-22: A cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection

Cytokine and Growth Factor Reviews

Volumn 21, Issue 5, 2010, Pages 365-379

  Witte, Ellen ^a   Witte, Katrin ^a   Warszawska, Katarzyna ^a   Sabat, Robert ^a   Wolk, Kerstin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antimicrobial protein; Class II cytokine; Cytokine receptor; Innate immunity; Psoriasis; Tissue damage

Indexed keywords

BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 22; INTERLEUKIN 22 BINDING PROTEIN; INTERLEUKIN 22 RECEPTOR; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; CARCINOGENESIS; CELL REGENERATION; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EPIDERMIS CELL; FUNGUS IMMUNITY; HUMAN; INFECTION; INNATE IMMUNITY; LIVER CELL; LYMPHOID TISSUE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PARASITOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PSORIASIS; SIGNAL TRANSDUCTION; SOLID TUMOR; T LYMPHOCYTE SUBPOPULATION; TARGET CELL; TISSUE INJURY; VIRUS IMMUNITY;

ANIMALS; HUMANS; IMMUNITY, INNATE; INTERLEUKINS; KILLER CELLS, NATURAL; NATURAL KILLER T-CELLS; T-LYMPHOCYTE SUBSETS;

EID: 78649757427     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.08.002     Document Type: Article

References (160)

1. Dumoutier L., Louahed J., Renauld J.C. Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9. J Immunol 2000, 164(4):1814-1819.
2. Dumoutier L., Van Roost E., Colau D Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor. Proc Natl Acad Sci USA 2000, 97(18):10144-10149.
3. Xie M.H., Aggarwal S., Ho W.H., Foster J., Zhang Z., Stinson J., et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem 2000, 275(40):31335-31339.
4. Wolk K., Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev 2006, 17(5):367-380.
5. Savan R., Ravichandran S., Collins J.R., Sakai M., Young H.A. Structural conservation of interferon gamma among vertebrates. Cytokine Growth Factor Rev 2009, 20(2):115-124.
6. Pestka S., Krause C.D., Sarkar D., Walter M.R., Shi Y., Fisher P.B. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004, 22:929-979.
7. Nagem R.A., Colau D., Dumoutier L., Renauld J.C., Ogata C., Polikarpov I. Crystal structure of recombinant human interleukin-22. Structure (Camb) 2002, 10(8):1051-1062.
8. de Oliveira Neto M., Ferreira J.R., Colau D., Fischer H., Nascimento A.S., Craievich A.F., et al. Interleukin-22 forms dimers that are recognized by two interleukin-22R1 receptor chains. Biophys J 2008, 94(5):1754-1765.
9. Xu T., Logsdon N.J., Walter M.R. Crystallization and X-ray diffraction analysis of insect-cell-derived IL-22. Acta Crystallogr D Biol Crystallogr 2004, 60(Pt 7):1295-1298.
10. Logsdon N.J., Jones B.C., Allman J.C., Izotova L., Schwartz B., Pestka S., et al. The IL-10R2 binding hot spot on IL-22 is located on the N-terminal helix and is dependent on N-linked glycosylation. J Mol Biol 2004, 342(2):503-514.
11. Langer J.A., Cutrone E.C., Kotenko S. The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev 2004, 15(1):33-48.
12. Kotenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E., Dickensheets H., Donnelly R.P., et al. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem 2001, 276(4):2725-2732.
13. Sabat R., Wallace E., Endesfelder S., Wolk K. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets 2007, 11(5):601-612.
14. Logsdon N.J., Jones B.C., Josephson K., Cook J., Walter M.R. Comparison of interleukin-22 and interleukin-10 soluble receptor complexes. J Interferon Cytokine Res 2002, 22(11):1099-1112.
15. Li J., Tomkinson K.N., Tan X.Y., Wu P., Yan G., Spaulding V., et al. Temporal associations between interleukin 22 and the extracellular domains of IL-22R and IL-10R2. Int Immunopharmacol 2004, 4(5):693-708.
16. Wolk K., Witte E., Reineke U., Witte K., Friedrich M., Sterry W., et al. Is there an interaction between interleukin-10 and interleukin-22?. Genes Immun 2005, 6(1):8-18.
17. Reineke U., Schneider-Mergener J., Glaser R.W., Stigler R.D., Seifert M., Volk H.D., et al. Evidence for conformationally different states of interleukin-10: binding of a neutralizing antibody enhances accessibility of a hidden epitope. J Mol Recognit 1999, 12(4):242-248.
18. Gough D.J., Levy D.E., Johnstone R.W., Clarke C.J. IFNgamma signaling-does it mean JAK-STAT?. Cytokine Growth Factor Rev 2008, 19(5-6):383-394.
19. Lejeune D., Dumoutier L., Constantinescu S., Kruijer W., Schuringa J.J., Renauld J.C. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem 2002, 277(37):33676-33682.
20. Dumoutier L., de Meester C., Tavernier J., Renauld J.C. New activation modus of STAT3: a tyrosine-less region of the interleukin-22 receptor recruits STAT3 by interacting with its coiled-coil domain. J Biol Chem 2009, 284(39):26377-26384.
21. Wolk K., Kunz S., Asadullah K., Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members?. J Immunol 2002, 168(11):5397-5402.
22. Wolk K., Witte K., Witte E., Proesch S., Schulze-Tanzil G., Nasilowska K., et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008, 83(5):1181-1193.
23. Wolk K., Witte E., Wallace E., Docke W.D., Kunz S., Asadullah K., et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006, 36(5):1309-1323.
24. Chung Y., Yang X., Chang S.H., Ma L., Tian Q., Dong C. Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res 2006, 16(11):902-907.
25. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10(8):857-863.
26. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203(10):2271-2279.
27. Trifari S., Kaplan C.D., Tran E.H., Crellin N.K., Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009, 10(8):864-871.
28. Zheng Y., Danilenko D.M., Valdez P., Kasman I., Eastham-Anderson J., Wu J., et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445(7128):648-651.
29. Billiau A., Matthys P. Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev 2009, 20(2):97-113.
30. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441(7090):235-238.
31. Brustle A., Heink S., Huber M., Rosenplanter C., Stadelmann C., Yu P., et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007, 8(9):958-966.
32. Crome S.Q., Wang A.Y., Kang C.Y., Levings M.K. The role of retinoic acid-related orphan receptor variant 2 and IL-17 in the development and function of human CD4+ T cells. Eur J Immunol 2009, 39(6):1480-1493.
33. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126(6):1121-1133.
34. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441(7090):231-234.
35. Spolski R., Leonard W.J. Cytokine mediators of Th17 function. Eur J Immunol 2009, 39(3):658-661.
36. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24(2):179-189.
37. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28(1):29-39.
38. Blanco P., Palucka A.K., Pascual V., Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev 2008, 19(1):41-52.
39. Fitzgerald-Bocarsly P., Dai J., Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev 2008, 19(1):3-19.
40. Liu Y., Yang B., Zhou M., Li L., Zhou H., Zhang J., et al. Memory IL-22-producing CD4+ T cells specific for Candida albicans are present in humans. Eur J Immunol 2009, 39(6):1472-1479.
41. Volpe E., Servant N., Zollinger R., Bogiatzi S.I., Hupe P., Barillot E., et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008, 9(6):650-657.
42. Manel N., Unutmaz D., Littman D.R. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008, 9(6):641-649.
43. Stockinger B., Veldhoen M., Hirota K. Modulation of Th17 development and function by activation of the aryl hydrocarbon receptor-the role of endogenous ligands. Eur J Immunol 2009, 39(3):652-654.
44. Veldhoen M., Hirota K., Christensen J., O'Garra A., Stockinger B. Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 2009, 206(1):43-49.
45. Veldhoen M., Hirota K., Westendorf A.M., Buer J., Dumoutier L., Renauld J.C., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453(7191):106-109.
46. Alam M.S., Maekawa Y., Kitamura A., Tanigaki K., Yoshimoto T., Kishihara K., et al. Notch signaling drives IL-22 secretion in CD4+ T cells by stimulating the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 2010, 107(13):5943-5948.
47. Ciric B., El-behi M., Cabrera R., Zhang G.X., Rostami A. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 2009, 182(9):5296-5305.
48. Hamada H., Garcia-Hernandez Mde L., Reome J.B, Misra S.K., Strutt T.M., McKinstry K.K., et al. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 2009, 182(6):3469-3481.
49. Martin B., Hirota K., Cua D.J., Stockinger B., Veldhoen M. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009, 31(2):321-330.
50. Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31(2):331-341.
51. Monteleone G., Pallone F., Macdonald T.T. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev 2009, 20(2):185-191.
52. Dhiman R., Indramohan M., Barnes P.F., Nayak R.C., Paidipally P., Rao L.V., et al. IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion. J Immunol 2009, 183(10):6639-6645.
53. Cella M., Fuchs A., Vermi W., Facchetti F., Otero K., Lennerz J.K., et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009, 457(7230):722-725.
54. Luci C., Reynders A., Ivanov I.I., Cognet C., Chiche L., Chasson L., et al. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat Immunol 2009, 10(1):75-82.
55. Sanos S.L., Bui V.L., Mortha A., Oberle K., Heners C., Johner C., et al. RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells. Nat Immunol 2009, 10(1):83-91.
56. Satoh-Takayama N., Dumoutier L., Lesjean-Pottier S., Ribeiro V.S., Mandelboim O., Renauld J.C., et al. The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. J Immunol 2009, 183(10):6579-6587.
57. Satoh-Takayama N., Vosshenrich C.A., Lesjean-Pottier S., Sawa S., Lochner M., Rattis F., et al. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 2008, 29(6):958-970.
58. Hughes T., Becknell B., McClory S., Briercheck E., Freud A.G., Zhang X., et al. Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood 2009, 113(17):4008-4010.
59. Cupedo T., Crellin N.K., Papazian N., Rombouts E.J., Weijer K., Grogan J.L., et al. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat Immunol 2009, 10(1):66-74.
60. Marchesi F., Martin A.P., Thirunarayanan N., Devany E., Mayer L., Grisotto M.G., et al. CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles. Mucosal Immunol 2009, 2(6):486-494.
61. Crellin N.K., Trifari S., Kaplan C.D., Cupedo T., Spits H. Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 2010, 207(2):281-290.
62. Takatori H., Kanno Y., Watford W.T., Tato C.M., Weiss G., Ivanov I.I., et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009, 206(1):35-41.
63. Goto M., Murakawa M., Kadoshima-Yamaoka K., Tanaka Y., Nagahira K., Fukuda Y., et al. Murine NKT cells produce Th17 cytokine interleukin-22. Cell Immunol 2009, 254(2):81-84.
64. Wahl C., Wegenka U.M., Leithauser F., Schirmbeck R., Reimann J. IL-22-dependent attenuation of T cell-dependent (ConA) hepatitis in herpes virus entry mediator deficiency. J Immunol 2009, 182(8):4521-4528.
65. Wolk K., Kunz S., Witte E., Friedrich M., Asadullah K., Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004, 21(2):241-254.
66. Weber G.F., Schlautkotter S., Kaiser-Moore S., Altmayr F., Holzmann B., Weighardt H. Inhibition of interleukin-22 attenuates bacterial load and organ failure during acute polymicrobial sepsis. Infect Immun 2007, 75(4):1690-1697.
67. Aujla S.J., Chan Y.R., Zheng M., Fei M., Askew D.J., Pociask D.A., et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat Med 2008, 14(3):275-281.
68. Siegemund S., Schutze N., Schulz S., Wolk K., Nasilowska K., Straubinger R.K., et al. Differential IL-23 requirement for IL-22 and IL-17A production during innate immunity against Salmonella enterica serovar Enteritidis. Int Immunol 2009, 21(5):555-565.
69. Raffatellu M., George M.D., Akiyama Y., Hornsby M.J., Nuccio S.P., Paixao T.A., et al. Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host Microbe 2009, 5(5):476-486.
70. Wang S.S., Asfaha S., Okumura T., Betz K.S., Muthupalani S., Rogers A.B., et al. Fibroblastic colony-forming unit bone marrow cells delay progression to gastric dysplasia in a helicobacter model of gastric tumorigenesis. Stem Cells 2009, 27(9):2301-2311.
71. Zheng Y., Valdez P.A., Danilenko D.M., Hu Y., Sa S.M., Gong Q., et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008, 14(3):282-289.
72. Buonocore S., Ahern P.P., Uhlig H.H., Ivanov I.I., Littman D.R., Maloy K.J., et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010, 464(7293):1371-1375.
73. Brand S., Dambacher J., Beigel F., Zitzmann K., Heeg M.H., Weiss T.S., et al. IL-22 mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro. Am J Physiol Gastrointest Liver Physiol 2007.
74. De Luca A, Zelante T, D'Angelo C, Zagarella S, Fallarino F, Spreca A, et al., IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol. May 5.
75. Munoz M., Heimesaat M.M., Danker K., Struck D., Lohmann U., Plickert R., et al. Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17. J Exp Med 2009, 206(13):3047-3059.
76. Scriba T.J., Kalsdorf B., Abrahams D.A., Isaacs F., Hofmeister J., Black G., et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 2008, 180(3):1962-1970.
77. Arias J.F., Nishihara R., Bala M., Ikuta K. High systemic levels of interleukin-10, interleukin-22 and C-reactive protein in Indian patients are associated with low in vitro replication of HIV-1 subtype C viruses. Retrovirology 2010, 7:15.
78. Bingold T.M., Ziesche E., Scheller B., Sadik C.D., Franck K., Just L., et al. Interleukin-22 Detected In Patients With Abdominal Sepsis. Shock 2010, March 9.
79. Dambacher J., Beigel F., Zitzmann K., Heeg M.H., Goke B., Diepolder H.M., et al. The role of interleukin-22 in hepatitis C virus infection. Cytokine 2008, 41(3):209-216.
80. Pan H., Hong F., Radaeva S., Gao B. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol 2004, 1(1):43-49.
81. Ma H.L., Liang S., Li J., Napierata L., Brown T., Benoit S., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008, 118(2):597-607.
82. Andoh A., Zhang Z., Inatomi O., Fujino S., Deguchi Y., Araki Y., et al. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 2005, 129(3):969-984.
83. Wolk K., Witte E., Hoffmann U., Doecke W.D., Endesfelder S., Asadullah K., et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol 2007, 178(9):5973-5981.
84. Sugimoto K., Ogawa A., Mizoguchi E., Shimomura Y., Andoh A., Bhan A.K., et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008, 118(2):534-544.
85. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Karow M., Flavell R.A. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007, 27(4):647-659.
86. Ikeuchi H., Kuroiwa T., Hiramatsu N., Kaneko Y., Hiromura K., Ueki K., et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum 2005, 52(4):1037-1046.
87. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007, 13(10):1173-1175.
88. Kreymborg K., Etzensperger R., Dumoutier L., Haak S., Rebollo A., Buch T., et al. IL-22 is expressed by Th17 cells in an IL-23-dependent fashion, but not required for the development of autoimmune encephalomyelitis. J Immunol 2007, 179(12):8098-8104.
89. Chang H., Hanawa H., Liu H., Yoshida T., Hayashi M., Watanabe R., et al. Hydrodynamic-based delivery of an interleukin-22-Ig fusion gene ameliorates experimental autoimmune myocarditis in rats. J Immunol 2006, 177(6):3635-3643.
90. Boniface K., Bernard F.X., Garcia M., Gurney A.L., Lecron J.C., Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005, 174(6):3695-3702.
91. Lecart S., Morel F., Noraz N., Pene J., Garcia M., Boniface K., et al. IL-22, in contrast to IL-10, does not induce Ig production, due to absence of a functional IL-22 receptor on activated human B cells. Int Immunol 2002, 14(11):1351-1356.
92. Aggarwal S., Xie M.H., Maruoka M., Foster J., Gurney A.L. Acinar cells of the pancreas are a target of interleukin-22. J Interferon Cytokine Res 2001, 21(12):1047-1053.
93. Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S.T., Otte J.M., et al. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol 2006, 290(4):G827-G838.
94. Wolk K., Haugen H.S., Xu W., Witte E., Waggie K., Anderson M., et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009, 87(5):523-536.
95. Nagalakshmi M.L., Rascle A., Zurawski S., Menon S., de Waal Malefyt R. Interleukin-22 activates STAT3 and induces IL-10 by colon epithelial cells. Int Immunopharmacol 2004, 4(5):679-691.
96. Whittington H.A., Armstrong L., Uppington K.M., Millar A.B. Interleukin-22: a potential immunomodulatory molecule in the lung. Am J Respir Cell Mol Biol 2004, 31(2):220-226.
97. Dumoutier L., Lejeune D., Colau D., Renauld J.C. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001, 166(12):7090-7095.
98. Gruenberg B.H., Schoenemeyer A., Weiss B., Toschi L., Kunz S., Wolk K., et al. A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta. Genes Immun 2001, 2(6):329-334.
99. Kotenko S.V., Izotova L.S., Mirochnitchenko O.V., Esterova E., Dickensheets H., Donnelly R.P., et al. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol 2001, 166(12):7096-7103.
100. Xu W., Presnell S.R., Parrish-Novak J., Kindsvogel W., Jaspers S., Chen Z., et al. A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist. Proc Natl Acad Sci USA 2001, 98(17):9511-9516.
101. Wei C.C., Ho T.W., Liang W.G., Chen G.Y., Chang M.S. Cloning and characterization of mouse IL-22 binding protein. Genes Immun 2003, 4(3):204-211.
102. Weiss B., Wolk K., Grunberg B.H., Volk H.D., Sterry W., Asadullah K., et al. Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart. Genes Immun 2004, 5(5):330-336.
103. Jones B.C., Logsdon N.J., Walter M.R. Structure of IL-22 bound to its high-affinity IL-22R1 chain. Structure 2008, 16(9):1333-1344.
104. de Moura P.R., Watanabe L., Bleicher L., Colau D., Dumoutier L., Lemaire M.M., et al. Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22. FEBS Lett 2009, 583(7):1072-1077.
105. Dumoutier L., Leemans C., Lejeune D., Kotenko S.V., Renauld J.C. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001, 167(7):3545-3549.
106. Wilson M.S., Feng C.G., Barber D.L., Yarovinsky F., Cheever A.W., Sher A., et al. Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J Immunol 2010, 184(8):4378-4390.
107. Harder J., Schroder J.M. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol 2005, 77(4):476-486.
108. Sa S.M., Valdez P.A., Wu J., Jung K., Zhong F., Hall L., et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007, 178(4):2229-2240.
109. Wolk K., Witte E., Warszawska K., Schulze-Tanzil G., Witte K., Philipp S., et al. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009, 39(12):3570-3581.
110. Blumberg H., Conklin D., Xu W.F., Grossmann A., Brender T., Carollo S., et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001, 104(1):9-19.
111. Radaeva S., Sun R., Pan H.N., Hong F., Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004, 39(5):1332-1342.
112. Schulz S.M., Kohler G., Schutze N., Knauer J., Straubinger R.K., Chackerian A.A., et al. Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol 2008, 181(11):7891-7901.
113. Shioya M., Andoh A., Kakinoki S., Nishida A., Fujiyama Y. Interleukin 22 receptor 1 expression in pancreas islets. Pancreas 2008, 36(2):197-199.
114. Heilmann K., Hoffmann U., Witte E., Loddenkemper C., Sina C., Schreiber S., et al. Osteopontin as two-sided mediator of intestinal inflammation. J Cell Mol Med 2009, 13(6):1162-1174.
115. Sodek J., Batista Da Silva A.P., Zohar R. Osteopontin and mucosal protection. J Dent Res 2006, 85(5):404-415.
116. Wang K.X., Denhardt D.T. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev 2008, 19(5-6):333-345.
117. Fiedler F., Croissant N., Rehbein C., Iovanna J.L., Dagorn J.C., van Ackern K., et al. Acute-phase response of the rat pancreas protects against further aggression with severe necrotizing pancreatitis. Crit Care Med 1998, 26(5):887-894.
118. Gironella M., Iovanna J.L., Sans M., Gil F., Penalva M., Closa D., et al. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut 2005, 54(9):1244-1253.
119. Heller A., Fiedler F., Schmeck J., Luck V., Iovanna J.L., Koch T. Pancreatitis-associated protein protects the lung from leukocyte-induced injury. Anesthesiology 1999, 91(5):1408-1414.
120. Sekikawa A., Fukui H., Suzuki K., Karibe T., Fujii S., Ichikawa K., et al. Involvement of the IL-22/REG Ialpha axis in ulcerative colitis. Lab Invest 2010, 90(3):496-505.
121. Glaser R., Harder J., Lange H., Bartels J., Christophers E., Schroder J.M. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol 2005, 6(1):57-64.
122. Holmes M.A., Paulsene W., Jide X., Ratledge C., Strong R.K. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure 2005, 13(1):29-41.
123. Sohnle P.G., Hunter M.J., Hahn B., Chazin W.J. Zinc-reversible antimicrobial activity of recombinant calprotectin (migration inhibitory factor-related proteins 8 and 14). J Infect Dis 2000, 182(4):1272-1275.
124. Michalek M., Gelhaus C., Hecht O., Podschun R., Schroder J.M., Leippe M., et al. The human antimicrobial protein psoriasin acts by permeabilization of bacterial membranes. Dev Comp Immunol 2009, 33(6):740-746.
125. Cash H.L., Whitham C.V., Behrendt C.L., Hooper L.V. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 2006, 313(5790):1126-1130.
126. Liang S.C., Long A.J., Bennett F., Whitters M.J., Karim R., Collins M., et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J Immunol 2007, 179(11):7791-7799.
127. Lin Y., Ritchea S., Logar A., Slight S., Messmer M., Rangel-Moreno J., et al. Interleukin-17 is required for T helper 1 cell immunity and host resistance to the intracellular pathogen Francisella tularensis. Immunity 2009, 31(5):799-810.
128. Yao S., Huang D., Chen C.Y., Halliday L., Zeng G., Wang R.C., et al. Differentiation, distribution and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosis. PLoS Pathog 2010, 6(2):e1000789.
129. Misse D., Yssel H., Trabattoni D., Oblet C., Lo Caputo S., Mazzotta F., et al. IL-22 participates in an innate anti-HIV-1 host-resistance network through acute-phase protein induction. J Immunol 2007, 178(1):407-415.
130. Pagliaccetti N.E., Chu E.N., Bolen C.R., Kleinstein S.H., Robek M.D. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology 2010, 401(2):197-206.
131. Hennig B.J., Frodsham A.J., Hellier S., Knapp S., Yee L.J., Wright M., et al. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int 2007, 27(8):1134-1143.
132. Levillayer F., Mas M., Levi-Acobas F., Brahic M., Bureau J.F. Interleukin 22 is a candidate gene for Tmevp3, a locus controlling Theiler's virus-induced neurological diseases. Genetics 2007, 176(3):1835-1844.
133. Genin P., Vaccaro A., Civas A. The role of differential expression of human interferon-a genes in antiviral immunity. Cytokine Growth Factor Rev 2009, 20(4):283-295.
134. Witte K., Witte E., Sabat R., Wolk K. IL-28A, IL-28B, and IL-29: Promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010, 21:237-251.
135. Feng Z., Jiang B., Chandra J., Ghannoum M., Nelson S., Weinberg A. Human beta-defensins: differential activity against candidal species and regulation by Candida albicans. J Dent Res 2005, 84(5):445-450.
136. Murthy A.R., Lehrer R.I., Harwig S.S., Miyasaki K.T. In vitro candidastatic properties of the human neutrophil calprotectin complex. J Immunol 1993, 151(11):6291-6301.
137. Conti H.R., Shen F., Nayyar N., Stocum E., Sun J.N., Lindemann M.J., et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med 2009, 206(2):299-311.
138. Kisand K., Boe Wolff A.S., Podkrajsek K.T., Tserel L., Link M., Kisand K.V., et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines. J Exp Med 2010, 207(2):299-308.
139. Pitta M.G., Romano A., Cabantous S., Henri S., Hammad A., Kouriba B., et al. IL-17 and IL-22 are associated with protection against human kala azar caused by Leishmania donovani. J Clin Invest 2009, 119(8):2379-2387.
140. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., et al. Stat3 as an oncogene. Cell 1999, 98(3):295-303.
141. Chan K.S., Sano S., Kataoka K., Abel E., Carbajal S., Beltran L., et al. Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene 2008, 27(8):1087-1094.
142. Thompson CL, Plummer SJ, Tucker TC, Casey G, Li L. Interleukin-22 genetic polymorphisms and risk of colon cancer. Cancer Causes Control. Mar 26.
143. Nagakawa H., Shimozato O., Yu L., Takiguchi Y., Tatsumi K., Kuriyama T., et al. Expression of interleukin-22 in murine carcinoma cells did not influence tumour growth in vivo but did improve survival of the inoculated hosts. Scand J Immunol 2004, 60(5):449-454.
144. Weber G.F., Gaertner F.C., Erl W., Janssen K.P., Blechert B., Holzmann B., et al. IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J Immunol 2006, 177(11):8266-8272.
145. Zhang W., Chen Y., Wei H., Zheng C., Sun R., Zhang J., et al. Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts. Clin Cancer Res 2008, 14(20):6432-6439.
146. Bard J.D., Gelebart P., Anand M., Amin H.M., Lai R. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma. Leukemia 2008, 22(8):1595-1603.
147. Guttman-Yassky E., Lowes M.A., Fuentes-Duculan J., Zaba L.C., Cardinale I., Nograles K.E., et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 2008, 181(10):7420-7427.
148. Nograles K.E., Zaba L.C., Shemer A., Fuentes-Duculan J., Cardinale I., Kikuchi T., et al. IL-22-producing " T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009, 123(6). 1244-52 e2.
149. Pickert G., Neufert C., Leppkes M., Zheng Y., Wittkopf N., Warntjen M., et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009, 206(7):1465-1472.
150. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Stevens S., Flavell R.A. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29(6):947-957.
151. Geboes L., Dumoutier L., Kelchtermans H., Schurgers E., Mitera T., Renauld J.C., et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 2009, 60(2):390-395.
152. Gangemi S., Parisi P., Ricciardi L., Saitta S., Minciullo P.L., Cristani M.T., et al. Is interleukin-22 a possible indicator of chronic heart failure's progression?. Arch Gerontol Geriatr 2010, 50(3):311-314.
153. Cheng F., Guo Z., Xu H., Yan D., Li Q. Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2009, 68(4):604-606.
154. Pan H.F., Zhao X.F., Yuan H., Zhang W.H., Li X.P., Wang G.H., et al. Decreased serum IL-22 levels in patients with systemic lupus erythematosus. Clin Chim Acta 2009, 401(1-2):179-180.
155. Larsen J.M., Bonefeld C.M., Poulsen S.S., Geisler C., Skov L. IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis. J Allergy Clin Immunol 2009, 123(2):486-492.
156. Zhao Y., Yang J., Gao Y.D., Guo W. Th17 immunity in patients with allergic asthma. Int Arch Allergy Immunol 2010, 151(4):297-307.
157. Schnyder B., Lima C., Schnyder-Candrian S. Interleukin-22 is a negative regulator of the allergic response. Cytokine 2010, 50(2):220-227.
158. Endam L.M., Bosse Y., Filali-Mouhim A., Cormier C., Boisvert P., Boulet L.P., et al. Polymorphisms in the interleukin-22 receptor alpha-1 gene are associated with severe chronic rhinosinusitis. Otolaryngol Head Neck Surg 2009, 140(5):741-747.
159. Smith A.J., Humphries S.E. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009, 20(1):43-59.
160. Ramanathan M., Spannhake E.W., Lane A.P. Chronic rhinosinusitis with nasal polyps is associated with decreased expression of mucosal interleukin 22 receptor. Laryngoscope 2007, 117(10):1839-1843.